SCHEMBL4016793

SCHEMBL4016793

C=CCc1cc(O)cc(CC=C)c1OC(C(=O)OC)c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.41
MAPT P10636 4/20 0.41
ALDH1A1 P00352 4/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
F9 P00740 1/20 0.40
F10 P00742 1/20 0.40
THRB P10828 1/20 0.39
PTGDR Q13258 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
KDM4E B2RXH2 5/20 0.39
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.37
PPARG P37231 3/20 0.36
SLC22A12 Q96S37 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35
GCGR P47871 1/20 0.35
PPARA Q07869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4011903 0.84 PPARG (0.51) PPARGPPARA
SCHEMBL13924239 0.84 ALDH1A1 (0.44) L3MBTL1MAPTALDH1A1CYP1A2CYP3A4
SCHEMBL13947014 0.83 KDM4E (0.41) L3MBTL1MAPTALDH1A1F9F10
SCHEMBL9309038 0.74 PPARA (0.47) ALDH1A1F9F10KDM4ELMNA
SCHEMBL10305241 0.73 F9 (0.42) L3MBTL1ALDH1A1CYP1A2CYP3A4F9
SCHEMBL29236114 0.71 F9 (0.47) L3MBTL1ALDH1A1F9F10KDM4E
SCHEMBL1154849 0.70 L3MBTL1 (0.49) L3MBTL1ALDH1A1NPSR1
SCHEMBL12190675 0.69 F9 (0.44) L3MBTL1F9F10LMNAPPARG
SCHEMBL11565422 0.69 F9 (0.46) L3MBTL1MAPTF9F10PPARG
SCHEMBL9128213 0.68 L3MBTL1 (0.53) L3MBTL1MAPTF9F10THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495020-B2 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders MERCK & CO., INC. (US) 2009-02-24 US disclosed
US-7091230-B2 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders MERCK & CO., INC. (US) 2006-08-15 US disclosed
US-20060122242-A1 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders MERCK SHARP & DOHME CORP. 2006-06-08 US disclosed
EP-1366012-A4 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS MERCK & CO INC (US) 2005-11-02 EP disclosed
US-20040092596-A1 2-Aryloxy-2arylalkanoic acids for diabetes and lipid disorders MERCK SHARP & DOHME CORP. 2004-05-13 US disclosed
EP-1366012-A2 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS Merck & Co., Inc. (US) 2003-12-03 EP disclosed
WO-2002064094-A2 2-ARYLOXY-2-ARYLALKANOIC ACIDS FOR DIABETES AND LIPID DISORDERS MERCK & CO., INC. (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122242-A1 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders PPARA, PPARG, PPARD L3MBTL1 1582/4885MAPT 4627/4885ALDH1A1 650/4885
US-20040092596-A1 2-Aryloxy-2arylalkanoic acids for diabetes and lipid disorders PPARA, PPARG, PPARD L3MBTL1 1736/4885MAPT 4689/4885ALDH1A1 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.